In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2013 transferred altogether 137,000 Orion Corporation B-shares held by the company as a share reward for earning periods 2010-2012 and 2012 to the persons employed by the Orion Group and belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 24 March 2010. The price per share of the transferred shares is EUR 22.7936, which is the volume weighted average quotation of the Orion Corporation B-share on 1 March 2013. Accordingly, the total transaction price of the transferred shares is EUR 3,122,723.20.
After the share transfer, the total number of own B-shares held by Orion Corporation is 188,991.
Orion Corporation has informed about the Share-based Incentive Plan in a stock exchange release on 18 February 2010.
| Timo Lappalainen|
President and CEO
| Olli Huotari|
SVP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.